CN103501775A - 他喷他多的胃肠外给药 - Google Patents

他喷他多的胃肠外给药 Download PDF

Info

Publication number
CN103501775A
CN103501775A CN201280011685.9A CN201280011685A CN103501775A CN 103501775 A CN103501775 A CN 103501775A CN 201280011685 A CN201280011685 A CN 201280011685A CN 103501775 A CN103501775 A CN 103501775A
Authority
CN
China
Prior art keywords
composition
tapentadol
still
administration
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280011685.9A
Other languages
English (en)
Chinese (zh)
Inventor
T.克里斯托弗
S.K.K.英赫尔布雷希特
R.C.A.恩布雷希茨
E.武尔斯滕
K.席内
M.席勒
P.布洛姆斯-芬克
U.莱茵霍尔德
U.法伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to CN201710217173.2A priority Critical patent/CN107088226A/zh
Publication of CN103501775A publication Critical patent/CN103501775A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280011685.9A 2011-03-04 2012-03-02 他喷他多的胃肠外给药 Pending CN103501775A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710217173.2A CN107088226A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449317P 2011-03-04 2011-03-04
US61/449317 2011-03-04
EP11003602 2011-05-03
EP11003602.7 2011-05-03
PCT/EP2012/000905 WO2012119728A1 (en) 2011-03-04 2012-03-02 Parenteral administration of tapentadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710217173.2A Division CN107088226A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Publications (1)

Publication Number Publication Date
CN103501775A true CN103501775A (zh) 2014-01-08

Family

ID=44653043

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280011685.9A Pending CN103501775A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药
CN201710217173.2A Pending CN107088226A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710217173.2A Pending CN107088226A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Country Status (22)

Country Link
US (3) US20120225951A1 (enExample)
EP (2) EP3025710A1 (enExample)
JP (4) JP2014510067A (enExample)
KR (2) KR101903351B1 (enExample)
CN (2) CN103501775A (enExample)
AU (2) AU2012224953C1 (enExample)
BR (1) BR112013022213A2 (enExample)
CA (1) CA2828635C (enExample)
CY (1) CY1117426T1 (enExample)
DK (1) DK2680833T3 (enExample)
EA (2) EA028149B1 (enExample)
ES (1) ES2573414T3 (enExample)
HR (1) HRP20160400T1 (enExample)
HU (1) HUE027514T2 (enExample)
IL (1) IL227825A (enExample)
MX (1) MX348831B (enExample)
PL (1) PL2680833T3 (enExample)
PT (1) PT2680833E (enExample)
RS (1) RS54711B1 (enExample)
SI (1) SI2680833T1 (enExample)
WO (1) WO2012119728A1 (enExample)
ZA (1) ZA201306479B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103735500A (zh) * 2014-01-28 2014-04-23 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
CN107847471A (zh) * 2015-03-27 2018-03-27 格吕伦塔尔有限公司 他喷他多肠胃外给药的稳定制剂
CN109996533A (zh) * 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582366B1 (en) 2010-06-15 2015-10-28 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
TR201802128T4 (tr) * 2011-07-29 2018-03-21 Gruenenthal Gmbh İntratekal veya epidural yolla 3-[(1s,2s)-3-(dimetilamino)-1-etil-2-metilpropil]fenol uygulaması.
KR20150075408A (ko) 2012-11-01 2015-07-03 토렌트 파마슈티칼스 리미티드 비경구용 타펜타돌의 약학 조성물
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
WO2020232424A1 (en) * 2019-05-16 2020-11-19 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
EP4011369A1 (en) * 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269326A1 (en) * 2007-03-12 2008-10-30 Gruenenthal Gmbh Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain
CN101495447A (zh) * 2006-07-24 2009-07-29 詹森药业有限公司 (2r,3r)-3-(3-甲氧苯基)-n,n,2-三甲基戊胺的制备

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) * 1983-12-23 1984-02-01 Sterwin Ag Composition
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
HUP0300585A3 (en) * 2000-04-27 2003-09-29 Pfizer Prod Inc Process for the use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
AU2001222986A1 (en) * 2000-05-19 2001-12-03 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP4905616B2 (ja) * 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
ES2291780T3 (es) * 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
AU2006239313A1 (en) * 2005-04-28 2006-11-02 Najib Babul Methods and compositions for treating pain
BRPI0620586A2 (pt) * 2005-12-02 2011-11-16 Nastech Pharm Co formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento
RU2465263C2 (ru) * 2006-04-28 2012-10-27 Грюненталь Гмбх Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
BRPI0710682B8 (pt) 2006-04-28 2021-05-25 Gruenenthal Gmbh combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol
EP1905440A1 (de) * 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
JP2008266168A (ja) * 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
PL2596784T3 (pl) 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2674150C1 (ru) * 2008-09-05 2018-12-05 Грюненталь Гмбх Фармацевтическая комбинация
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
CN101961315B (zh) * 2010-09-10 2012-09-05 海南美兰史克制药有限公司 一种门冬氨酸鸟氨酸脂质体注射液

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495447A (zh) * 2006-07-24 2009-07-29 詹森药业有限公司 (2r,3r)-3-(3-甲氧苯基)-n,n,2-三甲基戊胺的制备
US20080269326A1 (en) * 2007-03-12 2008-10-30 Gruenenthal Gmbh Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘肖平: "双重功效镇痛药他喷他多的药理学研究与临床应用", 《实用疼痛学杂志》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration
CN103735500A (zh) * 2014-01-28 2014-04-23 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
WO2015113200A1 (zh) * 2014-01-28 2015-08-06 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
CN103735500B (zh) * 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
CN107847471A (zh) * 2015-03-27 2018-03-27 格吕伦塔尔有限公司 他喷他多肠胃外给药的稳定制剂
US11013701B2 (en) 2015-03-27 2021-05-25 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
CN109996533A (zh) * 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
US10898452B2 (en) 2016-09-23 2021-01-26 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol

Also Published As

Publication number Publication date
DK2680833T3 (en) 2016-05-23
WO2012119728A1 (en) 2012-09-13
US20160106688A1 (en) 2016-04-21
US20200215003A1 (en) 2020-07-09
JP2014510067A (ja) 2014-04-24
AU2012224953B2 (en) 2017-01-05
AU2012224953A1 (en) 2013-09-19
HRP20160400T1 (hr) 2016-05-20
EP2680833A1 (en) 2014-01-08
ZA201306479B (en) 2014-05-28
SI2680833T1 (sl) 2016-06-30
CA2828635C (en) 2020-01-14
IL227825A0 (en) 2013-09-30
JP2018021050A (ja) 2018-02-08
CY1117426T1 (el) 2017-04-26
RS54711B1 (sr) 2016-08-31
CN107088226A (zh) 2017-08-25
AU2012224953C1 (en) 2017-07-13
MX2013010046A (es) 2013-12-16
KR101970468B1 (ko) 2019-04-19
JP2023075244A (ja) 2023-05-30
BR112013022213A2 (pt) 2017-05-02
ES2573414T3 (es) 2016-06-07
EA201300990A1 (ru) 2014-02-28
EP3025710A1 (en) 2016-06-01
CA2828635A1 (en) 2012-09-13
EP2680833B1 (en) 2016-03-02
AU2017202214A1 (en) 2017-04-27
EA024193B1 (ru) 2016-08-31
JP2022033863A (ja) 2022-03-02
MX348831B (es) 2017-06-30
PT2680833E (pt) 2016-06-09
EA201600088A1 (ru) 2016-07-29
KR20180064568A (ko) 2018-06-14
HK1194964A1 (zh) 2014-10-31
JP6837944B2 (ja) 2021-03-03
HUE027514T2 (en) 2016-10-28
KR101903351B1 (ko) 2018-10-04
PL2680833T3 (pl) 2016-08-31
KR20140017587A (ko) 2014-02-11
IL227825A (en) 2017-07-31
EA028149B1 (ru) 2017-10-31
US20120225951A1 (en) 2012-09-06
AU2017202214B2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
JP6837944B2 (ja) タペンタドールの非経口的投与
US8314083B2 (en) Non-sedating antihistamine injection formulations and methods of use thereof
EP3287123B1 (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
KR20150132381A (ko) S-케타민 하이드로클로라이드의 약제학적 조성물
JP2019142972A (ja) タペンタドールの非経口的投与
HK1224568A1 (en) Parenteral administration of tapentadol
HK1194964B (en) Parenteral administration of tapentadol
HK1240495A1 (en) Parenteral administration of tapentadol
HK40019541A (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
HK1250655B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
HK1194965A (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
HK40030923A (en) Aqueous pharmaceutical formulation of tapentadol for oral administration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140108

WD01 Invention patent application deemed withdrawn after publication